AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED
The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized.
Provided is a method for preventing the disturbance of vaginal bacterial flora during the menstrual period and improving the vaginal bacterial flora. One aspect of the present invention is a sanitary product carrying lactoferrin or a composition comprising lactoferrin and an auxiliary substance. Also provided is a kit comprising a sanitary product, and lactoferrin or the composition comprising lactoferrin and an auxiliary substance.
AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED
The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized.
Provided is a method for preventing the disturbance of vaginal flora during the menstrual period and improving vaginal flora. One aspect of the present invention is a sanitary product bearing lactoferrin or a composition including lactoferrin and an auxiliary substance. Also provided is a kit that includes the sanitary product and the lactoferrin or the composition including lactoferrin and an auxiliary substance.
A61F 13/15 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the bodySupporting or fastening means thereforTampon applicators
A61F 13/20 - Tampons, e.g. catamenial tamponsAccessories therefor
A61F 13/511 - Topsheet, i.e. the permeable cover or layer facing the skin
A61L 15/32 - Proteins, polypeptidesDegradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
5.
AGENT AND COMPOSITION FOR IMPROVING INTRAUTERINE BACTERIAL FLORA, AND METHOD FOR DETERMINING WHETHER INTRAUTERINE BACTERIAL FLORA HAS BEEN IMPROVED OR NORMALIZED
The purpose of the present invention is to provide an agent for improving intrauterine bacterial flora, and a method for determining whether intrauterine bacterial flora has been improved or normalized. An aspect of the present invention is an agent for improving intrauterine bacterial flora that contains lactoferrin or a salt thereof as an active ingredient. Additionally provided are: an agent or composition for improving intrauterine flora or treating or preventing diseases caused by the imbalance of intrauterine bacterial flora, the agent or composition containing lactoferrin or a salt thereof; a method for treating or preventing diseases caused by imbalance of intrauterine bacterial flora, the method comprising administrating the agent or composition; and a method for determining whether intrauterine bacterial flora has been improved or normalized.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
The purpose of the present invention is to develop a medicine for diseases related to glycosaminoglycan functions with less side effects. Provided is a glycosaminoglycan inhibitor or promoter that comprises lactoferrin or a derivative thereof.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly diabetes, obesity, and hyperlipidemia. The present invention provides a combination therapy using a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof with metformin.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.
The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY (Japan)
Inventor
Takeuchi Takashi
Kagaya Shinji
Hoshino Tatsuo
Abstract
The present invention pertains to an anticancer therapeutic adjuvant which contains a protein having lactoferrin activity and which is intended for concomitant use with a platinum-based anticancer drug composition, enhances anticancer activity of said composition, and reduces pain derived from said composition. This protein having lactoferrin activity provides a disease preventive or therapeutic agent that is intended for concomitant use with a platinum-based anticancer drug, that is useful in reducing pain derived from a platinum-based anticancer drug composition, and that further enhances anticancer activity.
The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve AMPK dysregulation. The present invention provides a compound presented by formula I, a pharmaceutically acceptable salt or a solvate thereof.
C07C 49/753 - Unsaturated compounds containing a keto group being part of a ring containing ether groups, groups, groups, or groups
A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07C 47/575 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing ether groups, groups, groups, or groups
C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
C07C 251/44 - Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups being part of a ring other than a six-membered aromatic ring
C07C 251/48 - Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
C07C 251/58 - Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 251/62 - Oximes having oxygen atoms of oxyimino groups esterified
C07D 295/08 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
C07D 305/04 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
13.
WHITE BLOOD CELL EXTRACELLULAR TRAP FORMATION INHIBITOR
The purpose of the present invention is to provide a new drug that inhibits the formation of white blood cell extracellular traps. This invention provides: a white blood cell extracellular trap formation inhibitor that includes lactoferrin fragments; and a composition for treating diseases that is related to the formation of white blood cell extracellular traps and that includes lactoferrin.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The purpose of the present invention is to provide microparticles having an average particle size of 100 μm or less. The present invention provides microparticles having an average particle size of 100 μm or less and a method for producing the same. The present invention also provides a drug, food, and feed containing microparticles having an average particle size of 100 μm or less.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
B01J 2/04 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
15.
INHIBITOR OF EXTRACELLULAR TRAP FORMATION IN LEUKOCYTES
The purpose of the present invention is to provide a novel drug for inhibiting extracellular trap formation in leukocytes. The invention provides an inhibitor of extracellular trap formation in leukocytes which contain lactoferrin, and a composition for treating disorders related to extracellular trap formation in leukocytes which contain lactoferrin.
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
The purpose of the invention is to provide: a lactoferrin fusion protein that retains the bioactivity of natural lactoferrin, significantly prolongs the in vivo lifespan, and has better clinical utility than natural lactoferrin and recombinant lactoferrin; and a method for producing the same. The invention provides a fusion protein of: a protein or peptide containing an FcRn binding region; and lactoferrin or a lactoferrin bioactive fragment or peptide; wherein the fusion protein is represented by (LF-s-Y)n or (Y-s-LF)n (in the formula, LF represents lactoferrin or a lactoferrin bioactive fragment or peptide; Y represents a protein or peptide containing an FcRn binding region; s represents a sequence of any 0-10 amino acids; and n represents an integer of 1-10), or a variant thereof.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided are a complex of lactoferrin with a hydrophilic, linear and non-peptidic polymer which has a reduced antigenicity, imparts a pepsin-resistance, shows a prolonged life in vivo and, therefore, has a high clinical usefulness, and a method of producing the same. Also provided are a lactoferrin complex which sustains the biological activity of natural lactoferrin at a definite ratio, shows a significantly prolonged life in vivo and is superior in clinical usefulness to natural lactoferrin, a method of producing the same and so on. A method of producing a polyethylene glycolated lactoferrin complex wherein linear polyethylene glycol (PEG) or a modified product thereof is covalently bonded to lactoferrin via an amide bond, characterized by comprising a step of reacting a liquid reaction mixture, which contains lactoferrin and a linear PEG derivative having a para-nitrophenyl group, under such conditions as allowing the formation of an amide group between the para-nitrophenyl group and lactoferrin as described above.
C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
It is intended to provide a complex of lactoferrin with a nonpeptidic hydrophilic high-molecule, which has a lowered antigenicity and a pepsin-resistance imparted thereto, shows a prolonged life in vivo and has a high clinical usefulness, and a method of producing the same. Moreover, it is intended to provide a lactoferrin complex, which sustains the biological activity of natural lactoferrin at a specific level, shows a significantly prolonged life in vivo and is superior in clinical usefulness to natural lactoferrin, and a method of producing the same. As one embodiment, a biologically active complex of lactoferrin with a branched nonpeptidic hydrophilic high-molecule can be presented.
C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
It is intended to provide a drug for ameliorating symptoms or diseases caused by heavy metals (for example, Wilson’s disease, heavy metal toxication, aging, fulminant hepatitis and so on) which has a high safety without any fear of side effect, can eliminate heavy metals such as copper ion accumulated in excess in the living body to prevent or lessen the accumulation of the heavy metals in the living body, thereby eliminating or relieving the effects of the heavy metals; and compositions such as a medicinal composition, a food and a cosmetic containing the same. The drug and compositions as described above are characterized by containing lactoferrin and/or an active derivative of the same as the active ingredient.
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
patents
